Incretin Effect in Lean and Obese Subjects

NCT ID: NCT00803296

Last Updated: 2010-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incretin effect is markedly reduced in patients with type 2 diabetes. Data support the notion that this deficiency is a consequence of the diabetic state. However, the impact of insulin resistance on the incretin effect in obese individuals who uphold a normal glucose tolerance (NGT) despite their insulin resistant state remains to be elucidated. The primary aim of the present study is to evaluate the separate impact of one of the cornerstones of type 2 diabetic pathophysiology, namely insulin resistance, on the incretin effect in lean and obese patients with type 2 diabetes and in two matched normal-glucose tolerant groups of healthy control subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incretin Effect Insulin Resistance Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese patients with type 2 diabetes

Patients with type 2 diabetes and BMI\>33

Oral glucose tolerance test (OGTT)

Intervention Type OTHER

Isoglycemic intravenous glucose infusion

Intervention Type OTHER

Obese subjects with normal glucose tolerance

Subjects with normal glucose tolerance and BMI\>33

Oral glucose tolerance test (OGTT)

Intervention Type OTHER

Isoglycemic intravenous glucose infusion

Intervention Type OTHER

Lean subjects with type 2 diabetes

Patients with type 2 diabetes and BM\<25

Oral glucose tolerance test (OGTT)

Intervention Type OTHER

Isoglycemic intravenous glucose infusion

Intervention Type OTHER

Lean subjects with normal glucose tolerance

Subjects with normal glucose tolerance and BM\<25

Oral glucose tolerance test (OGTT)

Intervention Type OTHER

Isoglycemic intravenous glucose infusion

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral glucose tolerance test (OGTT)

Intervention Type OTHER

Isoglycemic intravenous glucose infusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with type 2 diabetes for at least 3 months
* Normal blood hemoglobin
* Informed consent

Exclusion Criteria

* Liver disease
* Diabetic nephropathy
* Treatment with medication that can not be stopped for 12 hours
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Gentofte, Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Hospital, Gentofte, Copenhagen

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tina Vilsbøll, MD DMSc

Role: STUDY_CHAIR

Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gentofte Hospital, University of Copenhagen

Hellerup, Copenhagen, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BMI-INK

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Incretins and Metabolism
NCT01607944 COMPLETED